B2M

Beta-2-microglobulin · P61769 · B2M on Sugi Atlas →

0 patent compounds predicted against B2M, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to B2M by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma PHASE2COMPLETED
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma PHASE2RECRUITING
Treatment of Myeloma in Patients = 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning PHASE2COMPLETED
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer PHASE2COMPLETED
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) PHASE2COMPLETED
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse PHASE2NOT_YET_RECRUITING
Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM PHASE2RECRUITING
Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma PHASE1/PHASE2COMPLETED
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma PHASE1/PHASE2RECRUITING
Horizon Two: HR NDMM (MMRC-100) PHASE2RECRUITING
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma PHASE1COMPLETED
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. PHASE1UNKNOWN
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma PHASE1COMPLETED
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy PHASE1RECRUITING
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma PHASE1COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma PHASE1COMPLETED
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma EARLY_PHASE1UNKNOWN
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma EARLY_PHASE1ACTIVE_NOT_RECRUITING
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms EARLY_PHASE1NOT_YET_RECRUITING
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma EARLY_PHASE1WITHDRAWN
Biomarkers of Cytomegalovirus Fetal Infection and Disease nanUNKNOWN
Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease nanRECRUITING
Cystatin c and Beta 2 Microglobulin in Thalassemic Children. nanUNKNOWN
Exploratory Clinical Study on the Safety of STR-P004 nanRECRUITING
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma nanRECRUITING
Oligosecretary Myeloma: Prevalence and Its Clinical Significance nanCOMPLETED
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma nanCOMPLETED
IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a B2M binder may also engage these)

ProteinNameSimilarity
P16213 1.000 P16213 →
P61771 1.000 P61771 →
P61770 1.000 P61770 →
O77521 1.000 O77521 →
Q71UN4 1.000 Q71UN4 →
Q71UN7 1.000 Q71UN7 →
O77534 1.000 O77534 →
O77523 1.000 O77523 →
P63060 1.000 P63060 →
P63064 1.000 P63064 →
Q6V7J5 1.000 Q6V7J5 →
Q71UN6 1.000 Q71UN6 →
O77529 1.000 O77529 →
P63061 1.000 P63061 →
O77532 1.000 O77532 →
P63062 1.000 P63062 →
Q6T672 1.000 Q6T672 →
P63069 1.000 P63069 →
Q71UN3 1.000 Q71UN3 →
Q6PZD3 1.000 Q6PZD3 →
O77526 1.000 O77526 →
O77531 1.000 O77531 →
P63071 1.000 P63071 →
O77530 1.000 O77530 →
O77537 1.000 O77537 →
O77536 1.000 O77536 →
P63070 1.000 P63070 →
P63068 1.000 P63068 →
Q71UN5 1.000 Q71UN5 →
O77535 1.000 O77535 →